Google
PBLS Stock Price & Analysis — Parabilis Medicines, Inc. Common Stock (Healthcare >> Biotechnology)
PBLS FAQ
What is PBLS's ROE?
Parabilis Medicines, Inc. Common Stock reports a Return on Equity (ROE) of -34.25%.
What is PBLS's dividend yield?
Parabilis Medicines, Inc. Common Stock offers a dividend yield of 0.00%.
What is PBLS's Quality Score?
Our AI rates PBLS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PBLS?
Our AI Timing Score for PBLS is 78 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PBLS belong to?
Parabilis Medicines, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
PBLS AI Analysis Summary
Our AI summary for PBLS: Parabilis Medicines, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -34.25%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 78/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 33.96
Price
-0.02
(-0.06%)
Day Change
|
|
|---|
PBLS, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 33.96 |
| PBV / Sector |
17.02 / 44,219.29
|
| Earning Per Share | -0.68 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
14.08 M
GREAT
|
| Average 1W Daily Value |
14.20 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:59 |
| Symbol | PBLS |
| Name | PARABILIS MEDICINES, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 120.73 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,156.18 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 30 Acorn Park Drive, Cambridge, MA, United States, 02140
Phone: (617) 945-9510
Website: https://parabilismed.com
Employees: 145
Sector: Healthcare >> Biotechnology
Description: Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap